07.19.2017 - By ReachMD
Guest: William C. Cromwell, MD, FAHA, FNLA
Ample data have demonstrated when LDL cholesterol and alternative measures – LDL-P or apo B – disagree, the risk for CVD events tracks with LDL-P or apo B. Additionally, it’s been demonstrated that when patients at high risk for CVD events were managed with the alternative measure LDL-P to 1,000 nmol/L versus less than 100 mg/dL, these patients experienced a 22 percent to 25 percent reduction in CVD events at 12, 24 and 36 months. Importantly, only a small number of individuals needed to be treated to an LDL-P of less than 1000 nmol/L to prevent one CVD event at 36 months. Dr. William Cromwell, medical director for cardiovascular disease at LabCorp, will address these issues. Click here to learn more in this special series.